



## ASX RELEASE

### NAME CHANGE TO BENITEC BIOPHARMA LIMITED

**Sydney, November 28, 2011:** At the company's Annual General Meeting held on 17 November 2011 members resolved to change the name of the company to Benitec Biopharma Limited to better reflect the company's current activities. The change of name has been registered with ASIC and ASX. The company's ASX Code will remain BLT.

#### For Further Information

Dr Peter French  
Chief Executive Officer  
Tel: +61 (0)412 457 595

[pfrench@benitec.com](mailto:pfrench@benitec.com)

#### About Benitec [www.benitec.com](http://www.benitec.com)

Benitec Limited is developing novel treatments for chronic and life-threatening conditions based on gene silencing using a transformational technology; DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian Securities Exchange (ASX) under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.